New drug aims to protect pancreas transplants

NCT ID NCT07503834

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests the safety of a drug called Anakinra in 15 people who have just received a pancreas transplant. The goal is to see if blocking a certain immune signal can prevent dangerous blood clots and improve transplant success. Researchers will closely monitor for side effects, especially severe infections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Anakinra

What this could lead to

If safe, this could point toward a way to reduce transplant complications and improve graft survival.

What could go wrong

This is a very early, small (15 people), open-label trial with no control group, so results may not be reliable or generalizable. There is also a risk of severe infections.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC TRANSPLANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Thromboinflammation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU Nantes

    Nantes, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••